Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
World game at war: why some European nations have threatened a World Cup boycott 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
SAN DIEGO, April 27, 2018 -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that that company will participate in the following investor conferences in May:
- William Blair 2nd Annual Late Stage Therapeutics Conference on Thursday, May 3, 2018 in New York
- Bank of America Merrill Lynch Health Care Conference on Wednesday, May 16, 2018 at 4:20 p.m. PT in Las Vegas
A webcast of the Bank of America Merrill Lynch Health Care Conference presentation will be available through the investor section of the AnaptysBio website. A replay of the webcast will be available for 90 days following the event.
About AnaptysBio
AnaptysBio is a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation. The company’s proprietary anti-inflammatory pipeline includes its anti-IL-33 antibody (ANB020) for the treatment of moderate-to-severe adult atopic dermatitis, moderate-to-severe baseline adult peanut allergy and severe adult eosinophilic asthma; its anti-IL-36R antibody (ANB019) for the treatment of rare inflammatory diseases, including generalized pustular psoriasis (GPP) and palmoplantar pustulosis (PPP), previously referred to as palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases where immune checkpoint receptors are insufficiently activated, which have demonstrated efficacy in an animal model of graft-versus-host disease. AnaptysBio’s antibody pipeline has been developed using its proprietary somatic hypermutation (SHM) platform, which uses in vitro SHM for antibody discovery and is designed to replicate key features of the human immune system to overcome the limitations of competing antibody discovery technologies. AnaptysBio has also developed multiple therapeutic antibodies in an immuno-oncology partnership with TESARO and an inflammation partnership with Celgene, including an anti-PD-1 antagonist antibody (TSR-042), an anti-TIM-3 antagonist antibody (TSR-022) and an anti-LAG-3 antagonist antibody (TSR-033), which are currently under clinical development with TESARO, and an anti-PD-1 checkpoint agonist antibody (CC-90006) currently in the clinic with Celgene.
Contact:
Monique Allaire
THRUST Investor Relations
617.895.9511
[email protected]
Chelcie Lister
THRUST Investor Relations
910.777.3049
[email protected]
